Anxiety disorders affect 25–50% of people with ADHD. One epidemiological study (Kessler, 2006) found that roughly 47% of adults with ADHD meet criteria for a comorbid anxiety disorder. A study of 353 adults with ADHD (Quenneville, 2022) found that 56% had at least one anxiety disorder. These are not separate problems that happen to coexist. The two conditions share genetics, neurobiology, and a bidirectional symptom interaction that makes each one worse.
The most common anxiety disorders seen alongside ADHD are phobias, generalised anxiety disorder (GAD), social anxiety, and separation anxiety. Panic disorder is less common but still overrepresented. Anxiety in ADHD is more prevalent in females (Solberg, 2018; n=40,103).
How They Feed Each Other
The ADHD-anxiety relationship is circular, not linear.
Shared Genetics
The genetic overlap is substantial. ADHD twin heritability is 0.76, and polygenic risk scores for ADHD significantly predict anxiety disorders (Fu et al., 2025).
Specific genetic findings:
- The NTAD gene cluster on chromosome 11q22-23, including the ANKK1-DRD2 region, is linked to comorbid GAD in adults with ADHD.
- NOS1 ex1f-VNTR short allele variants (21-repeat) are associated with severe depression and anxiety in ADHD.
- HTR1B polymorphisms show sex-specific effects - the G allele of rs11568817 is linked to GAD in females with ADHD. The rs6296C variant may be protective.
- At the protein level, 52% of ADHD effector proteins are shared or directly linked with depression-associated proteins. Anxiety disorders show the highest degree of overlap, with 8–34% shared effector proteins depending on the specific anxiety disorder.
Neurobiological Overlap
Clinical Consequences
Compared to ADHD alone, comorbid ADHD and anxiety produces a worse clinical picture across the board:
- More severe ADHD symptoms
- Higher number of additional psychiatric comorbidities
- Earlier age of onset
- Higher suicide risk
- More aggression (anxiety-driven tension combined with ADHD-driven poor impulse control)
- Higher hospitalisation rates
- More sleep disruption - delayed sleep onset and fewer than 6 hours per night
- Reduced academic and occupational functioning
- Lower self-esteem and weaker perceived social support
The Misdiagnosis Problem
ADHD and anxiety share surface-level symptoms that create diagnostic confusion. Difficulty concentrating, restlessness, irritability, and sleep problems appear in both conditions. An anxious person who can't focus because of worry may receive an ADHD diagnosis. A person with ADHD whose daily failures have generated anxiety may receive only an anxiety diagnosis.
Getting this wrong matters because the treatments are different. An SSRI prescribed for "anxiety" won't address the underlying executive dysfunction if ADHD is the primary driver. A stimulant prescribed for "ADHD" may initially worsen anxiety if anxiety is the primary condition. Accurate differential diagnosis - or recognition that both conditions are present - is essential for effective treatment.
Treatment Approaches
Lisdexamfetamine (Vyvanse) may have additional benefit through the TAAR1→DRD2 pathway, with computational modelling suggesting it can reverse 49 depression-associated effector proteins.
Sex-Specific Considerations
Females with ADHD show faster diurnal methylphenidate decline and may need split-dose regimens. Atomoxetine is preferred for females with greater emotional dysregulation. Menstrual cycle modulation of dopaminergic transmission may warrant dynamic dose adjustment. Males preferentially benefit from mindfulness-based approaches, while females respond better to structured psychoeducation.
Treatment Sequencing
Current consensus: treat the most severe or impairing condition first. If anxiety is the primary impairment, stabilise mood with antidepressants first, then reassess ADHD. If ADHD is the primary impairment, long-acting stimulants may indirectly improve anxiety by reducing daily failures. If both contribute equally, consider concurrent treatment but initiate sequentially to clarify side effects and attribute responses correctly.
References
- Fu, Y., et al. (2025). ADHD comorbid with anxiety and depression: review of genetic, neurobiological, and treatment evidence. Frontiers in Psychiatry.
- Kessler, R.C., et al. (2006). The prevalence and correlates of adult ADHD in the National Comorbidity Survey Replication. American Journal of Psychiatry, 163(4), 716–723.
- Quenneville, A.F., et al. (2022). Anxiety disorders in adults with ADHD. Journal of Attention Disorders, 26(5), 706–718.
- Solberg, B.S., et al. (2018). Gender differences in psychiatric comorbidity: a population-based study of 40,103 adults with ADHD. Acta Psychiatrica Scandinavica, 137(3), 176–186.
- Schatz, D.B. & Rostain, A.L. (2006). ADHD with comorbid anxiety. Journal of Attention Disorders, 10(2), 141–149.
- Barkley, R.A. (2015). Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment (4th ed.). Guilford Press.